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Summary.-Radiation survival curves for Lewis lung tumours in the lungs ranging
in size from 0-5 to 20 mm3 have been obtained, and a size-dependent variation in
hypoxic fraction was found. Cell-survival studies following treatment of various sizes
of s.c. tumours indicated that the effects of 60Co y-rays and the chemotherapeutic
agents 1,3-bas(2-chloroethyl)-1-nitrosourea (BCNU) and cyclophosphamide are
all size-dependent. Large pulmonary nodules which had regressed but had not
been cured by cyclophosphamide regrew with a radiosensitivity that was
characteristic of previously untreated tumours. The results give additional experi-
mental support to the clinical interest in early adjuvant therapy of micrometastases,
and sequential combined modality therapy for larger tumours.
THE relationship between tumour size
and therapeutic sensitivity has been the
subject of a number of studies. Experi-
ments from this laboratory have indicated
that cells in 0-5-mm3 pulmonarv metas-
tases of the Lewis lung (LL) tumour are
considerably more radiosensitive under
normal in situ conditions than those in
500-mm3 subcutaneous tumours (Shipley,
Stanley and Steel, 1975). At the level of
cell survival studied, the presence of a
hypoxic fraction could not be detected in
0-5-MM3 pulmonary tumours, whereas
the hypoxic fraction in large s.c. tumours
was estimated to be 0-36. Fu, Phillips and
Wharam (1976), working with the EMT6
tumour system, have also compared the
radiosensitivity of large s.c. tumours
with that of pulmonary nodules, and have
found the smaller tumours to be consider-
ably more radiosensitive and their hvpoxic
fraction to be correspondingly lower.
DeWys (1972) and Steel and Adams
(1975) have found independently, in
cell-survival studies with the LL tumour,
that small pulmonary nodules are more
sensitive to cyclophosphamide than are
larges.c.tumours. TwentymanandBleehen
(1976) saw no size-dependent effect when
the EMT6 tumour was treated with
cyclophosphamide, although their data
for the same tumour indicated that
sensitivity to BCNU decreased with
increasing tumour size.
Any effect oftumour size on therapeutic
response has important clinical implica-
tions for the use both of prophylactic
cytotoxic therapy against subclinical dis-
ease and of combined modality treatment
of larger tumours. The project described
in this report was designed to study in
greater detail the response of the LL
tumour to radiation and drug treatment
over a range of sizes, and to investigate
the radiosensitivity of regrowing lung
nodules which had been treated initially
with cyclophosphamide.
MATERIALS AND METHODS
Tumour system.-The Lewis lung (LL)
tumour, which arose spontaneously in a
C57BL mouse in 1951 (Sugiura and Stock,
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1955), was used throughout this study. I thas
been serially transplanted through many
generations of female C57BL mice of the
Institute of Cancer Research colony by the
s.c. injection into the flank of 105-106 viable
tumour cells.
In the series of experiments reported here,
tumours were either grown in the lung (from
i.v. injections of tumour cells), or s.c. in the
flank (from an injection of a suspension of
single tumour cells), or on the surface of the
dorsal muscle of the spine (by s.c. injection
of a tumour homogenate). The pulmonary
tumours were produced by injection into the
tail vein of 0-2-ml aliquots of cell suspension
each containing 104 viable tumour cells and
106 plastic microspheres (15 ,um diameter;
3M Company, Minneapolis, Minnesota). The
technique was originally employed in the
lung colony assay developed for this tumour
(Hill and Stanley, 1975a) and yielded in each
animal an average of 20 lung colonies which
were clearly visible after 10 days growth. By
allowing different periods of time to elapse
between implantation and experiment, it
was possible to vary the size of nodule
available for study.
This method of generating lung tumours
was also used in experiments which investi-
gated the ability of cyclophosphamide to
cure mice bearing a number of pulmonary
nodules. As these were long-term experi-
ments, it was necessary to prevent the pheno-
menon of "tail-trapping" of tumour cells
described by van den Brenk et al. (1975).
Consequently the tails of these animals were
irradiated with 60Co y-rays to a dose of
3000 rad 4 days after i.v. injection to sterilize
any residual cells.
Tumour homogenate suitable for s.c.
implantation was obtained by passing tumour
tissue fragments mixed with Eagle's basal
medium (Gibco-Biocult Laboratories Ltd,
Paisley) through a fine stainless steel mesh,
and then through needles of successively
narrower gauge until the suspension would
pass freely through a 25-gauge needle. The
homogenate was then diluted to 5 ml for
each gram of tissue used. Aliquots of 0-01-
0 04 ml, when injected between the skin and
dorsal muscle of the spine of recipient mice,
produced solid tumours ranging in volume
from 2 to 100 mm3 8 days after implantation.
Thus the response of a range of differently
sized tumours to a chosen treatment could
be measured on the same day.
Irradiation.-The irradiation of tumours
in situ was given as a whole-body dose to
unanaesthetized mice confined in perforated
perspex containers. The dose rate of 60Co y-
rays was 300-350 rad/min at 30 cm skin-to-
source distance. The mice were rotated
through 1800 halfway through the irradiation,
to give two equally weighted parallel-opposed
fields. For irradiation under hypoxic condi-
tions, mice were killed by asphyxiation with
N2 15 min before treatment. Tumours were
assayed immediately after both types of
irradiation treatment.
Cytotoxic drug treatment.-BCNU was
obtained from the Cancer Chemotherapy
National Service Center, Bethesda, Maryland,
U.S.A. Cyclophosphamide (Endoxana) was
obtained from W.B. Pharmaceuticals Ltd,
Bracknell, Berks. BCNU was initially dis-
solved in 100% ethanol before diluting with
0.9% w/v saline to give 10% ethanol in
the final solution. Cyclophosphamide was
made up in distilled water and 0.9% w/v
saline. The solutions of both drugs were
kept on ice before and during use, and were
injected i.p. in a volume of 0 5 ml within
15 min of reconstitution. In both cases,
tumours were assayed 2 h after drug adminis-
tration.
Cell-suspension technique and cell-survival
assay.-Single-cell suspensions of treated
and control tumours were prepared bytrypsin
digestion as previously described, with
volumes of reagents scaled down propor-
tionately when pulmonary tumours were used
(Hill and Stanley, 1975a).
The technique employed to assay the
colony-forming ability in agar of the tumour
cells surviving treatment was developed for
the LL tumour by Courtenay (1976). In this
method, surviving cells grow in soft agar to
produce spherical colonies containing up to
500 cells within 12 days. Using the LL
tumour, plating efficiencies were normally
between 30 and 50%, and it was possible to
measure values of survival down to about
5 x 10-4. Surviving fractions were calculated
as the ratio of the cloning efficiencies of
treated to untreated tumour cells. Standard
errors were calculated from the numbers of
colonies in treated and control groups, and
these are represented by error bars inFigs. 3a
and 3b. Each point represents a separate
determination, and the range of these at
any dose level indicates the degree of inter-
experiment variation.
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RESULTS
Effect of tumour size on cell survival after
cytotoxic therapy
(a) Chemotherapeutic agents.-Cell popu-
lations in 2-4-mm3 s.c. tumours sited on
the dorsal muscle of the spine were
markedly more sensitive to single doses of
BCNU and cyclophosphamide than were
500-mm3 s.c. tumours grown in the flank
(Figs. la and lb). The results indicate a
surviving fraction of 0 4 for cells from
500-mm3 tumours grown in animals which
had received 20 mg/kg BCNU 2 h before
assay, whereas survival after the same
dose of drug dropped to 0 01 for 2-mm3
s.c. tumours, and to 0 001 for 2-mm3
pulmonary nodules. A dose of 75 mg/kg
cyclophosphamide reduced survival in
4-mm3 s.c. tumours to 0 001, whereas in
200-mm3 s.c. tumours receiving the same
dose the surviving fraction was 0 05.
There was no evidence in either case that
s.c. tumours implanted in the flank
differed in their response to treatment
from s.c. tumours of the same size
implanted in the dorsal muscle of the
spine.
(b) Radiation.-The radiosensitivities of
cells from a range of sizes of s.c. and
pulmonary tumours were studied. The
results shown in Fig. 2 indicate consider-
able size-dependence at both sites; the
surviving fraction of cells from 1-mm3
tumourstreatedwith 1000radwasapproxi-
mately 0-001, and this value increased
with size, giving 0-1 as the survival of
500-mm3 s.c. tumours after the same dose
of radiation. In the overlapping region of
the size ranges no difference in sensitivity
between the two sites was detected.
Radiation dose-response curves for
20-mm3 and 6-mm3 pulmonary nodules
treated in air-breathing mice are shown
in Figs. 3a and 3b. Both sets ofdata appear
to indicate increased radioresistance at
high doses of radiation. This is consistent
with standard radiobiological models for
mixed-population survival curves in which
the radiation response at high doses is
determined by hypoxic cells. The lines
drawn through both sets of points are
those predicted theoretically by the multi-
target single-hit survival-curve model for
a mixed population of oxic and hypoxic
cells (Elkind and Whitmore, 1967). The
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FIG. la.-Cell survival for LL tumours of
different sizes treated 2 h previously with
20 mg/kg BCNU. v cells from s.c. tumours
on flank; A cells from s.c. tumours on
spine; E cells from pulmonary nodules.
Colony-forming ability assayed in vitro in
soft agar.
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FIG. lb.-Cell survival for LL tumours of
different sizes treated 2 h previously with
75 mg/kg cyclophosphamide. V cells from
s.c. tumours on flank; A cells from s.c.
tumours on spine. Colony-forming ability
assayed in vitro in soft agar.
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FIG. 2.-f6iCo y-ray cell survival for LL
tumours of different sizes treated in situ in
air-breathing unanaesthetized mice with
1000 rad. v cells from s.c. tumours on
flank; A cells from s.c. tumours on spine;
F1 cells from pulmonary nodules. Colony-
forming ability assayed in vitro in soft agar.
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FIG. 3a.-60Co y-ray cell survival curves for
LL tumour cells irradiated in 8itu either in
air-breathing mice [O, *, A I , *, CO],or
in N2-asphyxiated mice [0, V, A]. Open
symbols [1O, 0] for cells from 0-5-mm3
pulmonary tumours; closed symbols [*,
A, V, 0, Oj] for cells from 20-mm3
pulmonary tumours in air-breathing mice.
Symbols [A, V] for cells from 6-mm3 and
20-mm3 pulmonary tumours in N2-asphyxi-
ated mice. Colony-forming ability assayed
in vitro in soft agar.
parameters Do and N for an oxic popula-
tion were derived by linear regression
analysis on the data for 0-5 mm3 pul-
monary tumours treated in air-breathing
mice, using all results at dose levels which
yielded surviving fractions below 0l10
(Do oxic = 106 rad; N oxic = 20). Data
from pulmonary tumours in N2-4sphyxi-
ated mice were used to calculate the
same parameters for a hypoxic population
(Do hypoxic 275 rad; N hypoxic = 38).
Different values for hypoxic fraction
were substituted into the multi-target
equation to produce curves which best
fitted the data, and values for hypoxic
fraction of 0 05 and 0 01 were derived
for 20-mm3 and 6-mm3 pulmonary
tumours respectively.
Concurrent morphological studies on
paraffin sections of lung nodules of all
DOSE (rad)
FIG. 3b.-60Co y-ray cell survival curves for
LL tumour cells. Closed symbols [, *,
V, A] for cells from 4 separate experi-
ments on 6-mm3 pulmonary nodules
treated in 8itU in air-breathing unanaesthe-
tized mice. Broken lines are survival curves
for 0-5-mm3 pulmonary nodules in air-
breathing and N2-asphyxiated mice and
are taken directly from Fig. 3a. Colony-
forming ability assayed in vitro in soft agar.
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three sizes indicated that, although there
was no evidence of necrosis in 0-5-mm3
nodules, both 6-mm3 and 20-mm3 nodules
contained substantial areas of dead cells.
The effect of tumour size on regression and
regrowth after cyclophosphamide
The effect on the curability and radio-
sensitivity oflung nodules regrowing after
cyclophosphamide has also been assessed
with respect to tumour size at time of
treatment. An estimate oftumour volumes
at each of these different periods of time
after implantation was obtained by killing
untreated animals at dailyintervals during
the period 8-20 days after i.v. injection
of tumour cells, and fixing their lungs for
24 h in 10% formalin in saline. The median
colony volume at each interval was
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FIG. 4.-Regrowth of LL tumour pulmonary
nodules following a single dose (t) of
cyclophosphamide (300 mg/kg) given 16
days after implantation of the nodules by
i.v. injection of single-cell suspension.
* Median colony volume for nodules in
untreated animals; A, Fl, results of 2
separate experiments on cyclophosphamide
treated animals. Errors shown are quartile
values derived from distribution of tumour
sizes at each time point.
estimated by measuring the diameter
of 20-80 colonies on the lung surface with
the aid of a dissecting microscope fitted
with a calibrated eyepiece graticule.
The values derived from these measure-
ments were plotted against time and are
shown in Fig. 4 as the control group. The
error bars shown in Fig. 4 are the quartile
values derived from the range of sizes
observed at each interval.
Analysis of these data has already been
presented, and theoretical consideration
of the growth curve oflung nodules in the
microscopic phase (volume <0'1 mm3)
has already been described (Steel, Adams
and Stanley, 1976). Earlier investigations
in this laboratory indicated that, in the
size range of lung nodules studied, the
median intermitotic time for LL tumour
cells was about 11-12 h, and growth
fraction was in the range 55-70% (Hill
and Stanley, 1977). Little inter-experiment
variation ofgrowth rate has been observed
throughout the course of the present
experiments.
Previous results have shown that all
mice treated with 300 mg/kg cyclophos-
phamide within 10-11 days of tumour cell
injection were free of pulmonary disease
60 days later (Hill and Stanley, 1977).
If more than 11 days elapsed, a decline
in cure rate was observed, which resulted
in no 60-day survivors if treatment was
delayed until 19-20 days after implan-
tation. The approximate size of colonies
which can be cured by cyclophosphamide
is therefore 0-6 mm3, the median colony
volume at Day 11, although the maximum
size of tumour curable by 300 mg/kg
cyclophosphamide is more likely to be
represented by the upper limit of the
tumour size distribution at this timepoint.
Mice bearing pulmonary tumours that
had been growing for 16 days before
cyclophosphamide treatment were rarely
cured. The nodules underwent regression
and regrowth, reaching the nadir at 10-11
days aftertreatment, atwhichtimemedian
colony volume had fallen from 6 mm3
to less than 1 mm3 (Fig. 4). The radio-
sensitivity of tumour cells in lung nodules
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FIG. 5. 60Co y-ray survival curves for LL
tumour pulmonary nodules treated in situ
in air-breathing unanaesthetized mice.
*, cells from 6-mm3 pulmonary nodules;
A cells from 0.5-mm3 pulmonary nodules;
A cells from pulmonary nodules which
had received 300 mg/kg cyclophosphamide
10 days earlier, when median colony
volume was 6 mm3. Colony-forming ability
assayed in vitro in soft agar.
regrowing after cyclophosphamide was
evaluated and compared to the known
sensitivities of 0-5-mm3 and 6 mm3
untreated tumours. Mice carrying pul-
monary nodules received 300 mg/kg cyclo-
phosphamide 16 days after tumour cell
injection at which stage the median
tumour volume was estimated to be
approximately 6 mm3. Ten or 11 days
later groups of tumour-bearing mice were
given graded doses of radiation, and the
surviving fraction of cells was determined
by the agar colony assay. Pulmonary
tumours which had regressed from 6 mm3
to less than 1 mm3 showed a radiosensi-
tivity that was characteristic ofuntreated
0-5-mm3 nodules, with no evidence of a
hypoxic "tail" observed in survival
measurements down to 10-3 (Fig. 5).
Histological studies of the lungs
removed during this experiment indicated
that the great majority of cells in the
tumour nodule were dead within 3 days
of receiving the drug, and that growth
foci were not visible until 10-12 days
after treatment.
DISCUSSION
The influence of tumour size on thera-
peutic sensitivity is particularly relevant
to recent clinical interest in prophylactic
adjuvant chemotherapy for occult meta-
static disease. Results indicate that this
approach to treatment is producing a
significant increase in tumour-free survival
in patients treated for osteogenic sarcoma,
carcinoma of the breast and rhabdomyo-
sarcoma, diseases which have a high
probability ofearly metastasis (Jaffe et al.,
1974; Bonadonna et al., 1976; Heyn et al.,
1974). It is important to know the extent
to which cure of metastatic disease by
chemotherapy is limited by the size of the
deposits and, if this size is exceeded,
whether maximum sensitivity is regained
after the regression produced by an initial
treatment.
The present studies on the LL tumour
indicate that cells in large tumours are less
sensitive both to radiation and to cyto-
toxic drugs than cells in small nodules.
At the doses of each agent that we have
used, the level of cell kill measured in
TABLE.-Hypoxic Fraction vs Tnmouir Size in the LL Tumour in situ
Tumour Tumour Terminal Do (rad) Terminal Do (rad) Hypoxic fraction in
vol. site air-breathing mice hypoxic mice air-breathing mice
0 5mm3 Lung 106 (72-198) 275 (240-308) <0-005
6 mm3 Lung 275* 275* 0 01
20 mm3 Lung 275* 275* 0-05
500 mm3 Flank 315 (290-347) 307 (270-357) 0-36
* The data are consistent with the terminal D0 value found for 0-5 mm3 hypoxic tumours.
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1-2-mm3 nodules was about two decades
greater than in 500-mm3 s.c. tumours.
It can be inferred from the shapes of the
radiation survival curves for pulmonary
tumours (Figs. 3a and 3b) that the change
in sensitivity to radiation is largely due
to a marked increase in hypoxic fraction,
from undetectable levels in 0 5-mm3
nodules to about 0 05 in 15-20-mm3
tumours. These data are summarized in
the Table together withourearlierestimate
of0-36 for the hvpoxic fraction of500-mm3
s.c. tumours (Shipley et al., 1975). S.c.
and pulmonary tumours of the same size
appear to be equally radiosensitive (Fig. 2).
It seems unlikely, therefore, that the
absence of a detectable hypoxic fraction
in 1-mm3 tumour nodules growing in the
pulmonary bed is a direct result of the
extensive microvasculature of this organ.
Furthermore, the proportions of hypoxic
cells in lung nodules can be correlated
with histological changes: areas ofnecrosis
are not seen in 1-mm3 nodules, but are
visible in increasing amounts in 6-mm3
and 20-mm3 tumours.
The response ofLL tumours to cytotoxic
drugs also shows considerable size-depen-
dence. Figs. la and lb indicate that a
marked change in surviving fraction
occurs in the size range 1-100 mm3
for both cyclophosphamide and BCNU,
whereas the greatest change in sensitivity
to radiation appears to take place in
pulmonary tumours between 1 and 20 mm3
(Fig. 2). While the emergence of a measur-
able hypoxic fraction in tumours greater
than 5 mm3 explains the radiation results,
the reason for size-dependence of response
after drug treatment is not clear. Further-
more, unlike radiation treatment, BCNU
appears to be more effective against
pulmonary tumours than s.c. tumours of
the same size (Fig. Ia). A number of
studies have evaluated the response of
various experimental tumour systems to
this drug. Hagemann, Schenken and
Lesher (1973) have studied the response
of P815 x 2 mastocytoma cells grown in
culture, ascites and solid forms. They
found that solid tumours were far less
8
sensitive to the drug than either of the
other forms and suggested that this was a
consequence of the failure of the drug to
reach significant numbers of cells at risk.
Rosenblum et al. (1975) have studied the
effect of BCNU on a rat brain tumour
and found that the dose-response curve
for this drug was biphasic, withl little
extra cell kill noted at doses greater than
0 75 times the LD1o. They also considered
that accessibility of this drug to clono-
genic tumour cells might be the limiting
factor in its effectiveness.
Earlier results from this laboratory
indicated that BCNU treatment of the
murine tumour B16 melanoma left a
surviving population that was predomi-
nantly hypoxic (Hill and Stanley, 1975b),
suggesting that radiation and BCNU
spare the same sub-population of clono-
genic tumour cells. The implication of
this is not necessarily that the hypoxic
state of the cells is directly responsible for
their resistance to BCNU, as the failure
ofthe drug to reach these cells in adequate
concentrations would have the same effect.
The radiation dose-response curves from
6-mm3 and 20-mm3 pulmonary tumours
have been analysed by comparison with
curves predicted by a multi-target single-
hit model for a mixed oxic and hypoxic
cell population (Elkind and XVhitmore,
1967). For both tumour sizes studied, the
experimental data fitted quite closely to
the terminal region of the theoretical
curve predicted by the model (Figs. 3a
and 31)). Both sets of data show a gradual
inflexion before the radioresistant terminal
portion, and for 6-mm3 nodules, surviving
fractions between 041 and 0 01 lie consis-
tently above the line predicted by the
two-component model. These data may
be better interpreted in terms ofthe model
proposed by Tannock (1972), which allows
for a distribution of radiosensitivities
between that of maximally sensitive and
that of maximally resistant cells.
A large single dose of cyclophosphamide
produced only regression and some growth
delay in 16-day pulmonary tumours
(Fig. 4), resuilts which are qualitatively
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similar to those reported by Ovejera,
Johnson and Goldin (1975) for the same
tumour system. However, we have shown
that the pulmonary nodules regrowing
after cyclophosphamide treatment
appeared to be as radiosentisive as
previously untreated tumours (Fig. 5).
This indicates that the effect of drug
treatment on the tumour cells and stroma
did not impair the ability of the surviving
population to reoxygenate and proliferate.
These observations may be ofsome clinical
relevance in combined modality treatment
ofpulmonary disease, using chemotherapy
to shrink tumour nodules and conse-
quently to reduce the proportion of
hypoxic cells present in the tumour.
Suit and Maeda (1967), in studies on the
mammary carcinoma MDAH-MCa-4 in
C3H mice, observed that high pressure
02 administered during radiation treat-
ment was only modestly effective in
reducing the tumour-control dose for
250-mm3 tumours, whereas the same
treatment was much more effective against
0-6-mm3 nodules. It is possible that a
similar difference in response to high
pressure 02 may exist between 500-mm3
LL tumours with a 0-36 hypoxic fraction
and 6- and 20-mm3 pulmonary tumours
with hypoxic fractions of 0-01 and 0'05
respectively.
The principal finding of this study has
been that, although pulmonary nodules
less than 1 mm3 in volume are markedly
more sensitive to cytotoxic therapy than
larger tumours, this advantage rapidly
decreases over 4-5 volume doublings in
the case of radiation treatment, due to
developing hypoxia. There appear to be
critical size ranges over which cellular
sensitivity to drugs and radiation changes.
For radiation this takes place between
1 and 10 mm3, the size range over which
necrosis first becomes visible, whereas
the change in sensitivity to drug treat-
ment occurs in the size range between
1 and 100 mm8. It is not known whether
in man the critical size range may be
similar; in radiographically demonstrable
metastatic disease the size of the smallest
pulmonary deposits is considerably larger
than the most radiosensitive size reported
here. The concept of a critical size range
may have important implications both
for prophylactic therapy of occult meta-
static disease and for combined modality
treatment of larger tumour deposits. If
chemotherapy can shrink metastatic
nodules through this size range, then a
useful improvement may be gained in
subsequent radiotherapy.
The work contained in this report
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